[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100567794":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":56,"collaborators":60,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":66,"sex":72,"minAge":73,"maxAge":20,"enrollmentInfo":74,"targetDuration":20,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":86,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"University of Pittsburgh","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Sodium thiosulfate (STS)","EXPERIMENTAL","Open label, single-arm, receiving 1-5ml of STS (250mg\u002Fml) sodium thiosulfate (STS) injections to calcinosis lesions.",[13],"Drug: Sodium Thiosulfate (STS)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Sodium Thiosulfate (STS)","Depending on the size of the calcinosis lesion, 1-5ml of STS (250mg\u002Fml) will be used for injection under ultrasound guidance.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Robyn T Domsis, MD","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"Maureen M Laffoon, BS","CONTACT","412-648-7874","laffoonm@pitt.edu",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"UPMC Arthritis and Autoimmunity Center","RECRUITING","Pittsburgh","Pennsylvania","15213","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-79.99589,40.44062,{"lat":44,"lon":43},[47,51,54],{"name":48,"role":28,"phone":49,"phoneExt":20,"email":50},"Office Manager","412-647-6700","sclerodermaappts@upmc.edu",{"name":52,"role":28,"phone":53,"phoneExt":20,"email":30},"Research Coordinator","412-648-7871",{"name":55,"role":24,"phone":20,"phoneExt":20,"email":20},"Robyn T Domsic, MD",{"type":57,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"SPONSOR_INVESTIGATOR","Robyn T. Domsic, MD, MPH","Associate Professor",[61],{"name":62,"class":63},"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","NIH","100567794","phase-2-intralesional-injection-of-sts-in-treatment-of-calcinosis-100567794",false,"NCT06672822","Intralesional Injection of STS in Treatment of Calcinosis","An Open Label Evaluation of Intralesional Injection of Sodium Thiosulfate in the Treatment of Cutaneous or Tendon Calcinosis in Connective Tissue Disease","STSINJ","Inclusion Criteria:\n\n* Clinical diagnosis of systemic sclerosis, mixed connective tissue disease or inflammatory myopathy\n* Must be over 18 years of age\n* Participants must be competent to give informed consent\n* Participants must have radiographic evidence (xray or ultrasound) of calcinosis.\n* Participants must need symptomatic relief\n\nExclusion Criteria:\n\n• Pregnant women will be excluded","ALL","18 Years",{"count":75,"type":76},20,"ESTIMATED","INTERVENTIONAL",[79],"PHASE2","The specific objective of this study is to perform a small, open-label study to assess the safety and efficacy of intralesional, subcutaneous injection of STS on calcinosis symptoms and lesion size in systemic sclerosis (SSc), mixed connective tissue disease (MCTD) and dermatomyositis (DM) patients. Injection will be guided by ultrasound, lesion size assessed by ultrasound, and symptom burden by patient-reported outcome measures.",[82,83,84,85],"Systemic Sclerosis (SSc)","Dermatomyositis","Mixed Connective Tissue Disease (MCTD)","Calcinosis",[87],"calcinosis","2026-05-03",{"date":90,"type":91},"2026-05-05","ACTUAL",{"date":93,"type":91},"2025-03-17",{"date":95,"type":76},"2029-05-01",{"name":58,"class":6},1]